Louwai
@Louwai1
Doctor, neuroscientist, founder | CEO of CoSyne Therapeutics | Kickboxing pianist | @Harvard, @UniofOxford, @Cambridge_uni, @Kennedyscholars
2. The ability to synthesise individually meaningless data points into a highly predictive signal is a superpower. If a patient has pink hands (palmer erythema), it probably doesn’t mean anything. If they have a few blood vessels on their chest (spider naevi), it also probably…
📝 Unmet patient need: a glioblastoma story 🧠 Every year, around 3,200 people in the UK are diagnosed with glioblastoma (GBM), the most aggressive and deadly form of brain cancer. In the United States, that number is closer to 13,000 new cases annually. [1/11]
“If you can … watch the things you gave your life to, broken, And stoop and build ’em up with worn-out tools: If you can make one heap of all your winnings, And risk it on one turn of pitch-and-toss, And lose, and start again at your beginnings, And never breathe a…
Cells aren’t the only thing we grow at CoSyne Therapeutics – this year we are taking part in a chilli growing contest! We have lots of plants to brighten our office space in Cambridge. #CosyneTherapeutics #BrainCancerResearch #DrugDiscovery #Biotech
We are dedicated to changing the narrative around brain cancer. Our multidisciplinary team is focused on identifying vulnerabilities in this complex disease, pushing the boundaries of research to develop effective treatments. Learn more on our website: cosyne.com
The greatest achievements come from breaking through stress - when you learn to accept stress and know you can cope with it, your relationship with it changes.
Starting to think there is a pro-brain cancer lobby out there trying to stop drugs from being developed…
Fed up with how hard it is to fund brain tumour research. The science is there, but there is no will to get anything over the line.
Biotech is an industry of permissions. Permission from investors to do R&D for your idea, permission from FDA to run your trial & market the drug. This is a major frustration to newcomers, especially those from tech where agency & sheer will can bend the rules and be rewarded
6. See one, do one, teach one. Doctors often joke about this when learning a new medical procedure. The first time you ever see a procedure, you learn how it works. The second time you ever see it, you will be the one doing it. The third time you ever see it, you are probably…
5. Ownership of critical tasks needs to be allocated to named individuals. If someone has a cardiac arrest in public, and you say “somebody please call an ambulance”, nothing will happen at first. Everyone will think someone else is taking action. Instead, point to a specific…
4. Stand at the end of the bed with your hands behind your back. When you first lead a cardiac arrest (code blue), your temptation is to get involved with individual tasks like chest compressions. But if you get drawn into doing the actual tasks, you lose situational awareness.…
3. Will it change my management? Junior doctors often get in trouble for requesting generic panels of blood tests without being able to justify the rationale for each test. If you have a patient with a simple urinary tract infection who can go home with antibiotics, how will that…
1. Making decisions from imperfect information. At medical school, you get a vignette about a patient with specific symptoms and test results, and you feel very clever for making the diagnosis. In the real world, your patient might be a terrible historian and the computer system…
I’m going to start a series on things you learn in medicine that help you build a company
Delighted to announce that neurologist @KinanMuhammed is back at @NDCNOxford and has secured a place on the @acmedsci #FLIER Programme for #FutureLeaders in Innovation, Enterprise and Research ow.ly/FnjM50kxzpU